{
    "symbol": "NRXP",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 09:52:05",
    "content": " For the three month period ended September 30, 2022 R&D expenses totaled $4.1 million, compared to $6.3 million for the same period in 2021. For the nine month period ended September 30, 2022, R&D expenses totaled $12.6 million, as compared to $13.8 million for the same period in 2021. The net increase of $1.3 million is related to a decrease of $1.5 million in clinical trials and development expenses related to ZYESAMI, a decrease of $0.5 million in fees paid to regulatory and process development consultants, partially offset by an increase of $0.7 million in regulatory and process development costs. For the three month period ended September 30, 2022, G&A expenses totaled $5.0 million, compared to $13.8 million for the same period in 2021. For the nine month period ended September 30, 2022, G&A expenses totaled $21.9 million, as compared to $28.4 million for the same period in 2021. With the three month period ended September 30, 2022, our net loss was $9.1 million, as compared to a net loss of $37.0 million for the three month period ended September 30, 2021. For the nine month period ended September 30, 2022, our net loss was $29.5 million, as compared to -- with the net loss of $62.7 million for the same period in 2021."
}